Comparative Pharmacology
Head-to-head clinical analysis: OSMOVIST 190 versus VISIPAQUE 320.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OSMOVIST 190 versus VISIPAQUE 320.
OSMOVIST 190 vs VISIPAQUE 320
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast media with high osmolality, providing radiographic contrast by attenuating X-rays, primarily due to iodine content.
Iodinated nonionic radiocontrast agent that attenuates X-rays and enhances vascular and tissue contrast.
Intravenous administration of 0.1-0.3 mL/kg (0.19-0.57 mg iodine/kg) for adults; may repeat as needed. Maximum total dose 1.5 mL/kg.
Intravascular administration: Adult dose is 50-150 mL (16-48 g iodine) intravenously as a bolus or infusion, depending on the procedure. For CT imaging, typical dose is 75-150 mL at 1-3 mL/sec.
None Documented
None Documented
Terminal elimination half-life approximately 110 minutes. In renal impairment, half-life is prolonged, requiring dose adjustment.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. Clinically, clearance is prolonged in renal impairment, requiring dose adjustment.
Primarily renal (glomerular filtration). Excreted unchanged in urine, with less than 2% biliary/fecal excretion.
Primarily renal via glomerular filtration; approximately 95% of the dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent